Search research articles
Contact Us
Filters
Showing results (21-30 of 147) with videos related to
Page
of 15
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)
|
November 15, 2011
Should we switch to a 50-mg boosting dose of ritonavir for selected protease inhibitors?
Andrew Hill, Saye Khoo, Marta Boffito, et al.
Antiviral Therapy
|
April 9, 2008
Darunavir: pharmacokinetics and drug interactions
David Back, Vanitha Sekar, Richard M W Hoetelmans
AIDS (London, England)
|
May 21, 2009
Etravirine plasma levels in a patient with decompensated liver disease
Michael Aboud, Sheena Castelino, David Back, et al.
Antimicrobial Agents and Chemotherapy
|
June 13, 2012
Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval
Aylin Yilmaz, Victoria Watson, Laura Dickinson, et al.
AIDS (London, England)
|
October 3, 2003
Expression of P-glycoprotein, multidrug-resistance proteins 1 and 2 in CEM, CEM(VBL), CEM(E1000), MDCKII(MRP1) and MDCKII(MRP2) cell lines
Andrew Owen, Ruben C Hartkoorn, Saye Khoo, et al.
AIDS (London, England)
|
August 11, 2007
Stopping antiretroviral therapy
Stephen Taylor, Marta Boffito, Saye Khoo, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
October 18, 2005
Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry
Laura Dickinson, Lesley Robinson, John Tjia, et al.
Therapeutic Drug Monitoring
|
May 29, 2007
Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals
Laura Dickinson, David Back, Anton Pozniak, et al.
The Journal of Infectious Diseases
|
February 25, 2003
Differential expression of human immunodeficiency virus coreceptors, by CEM, CEMVBL, and CEM E1000 cells
Andrew Owen, Becky Chandler, Jenny Ford, et al.
Journal of the International AIDS Society
|
November 14, 2014
Should the dose of tenofovir be reduced to 200-250 mg/day, when combined with protease inhibitors?
Andrew Hill, Saye Khoo, David Back, et al.
Page
of 15
Search research articles
Search
Showing results (21-30 of 147) with videos related to
Sort By:
Page
of 15
Journal of Acquired Immune Deficiency Syndromes (1999)
|
November 15, 2011
Should we switch to a 50-mg boosting dose of ritonavir for selected protease inhibitors?
Andrew Hill, Saye Khoo, Marta Boffito, et al.
Antiviral Therapy
|
April 9, 2008
Darunavir: pharmacokinetics and drug interactions
David Back, Vanitha Sekar, Richard M W Hoetelmans
AIDS (London, England)
|
May 21, 2009
Etravirine plasma levels in a patient with decompensated liver disease
Michael Aboud, Sheena Castelino, David Back, et al.
Antimicrobial Agents and Chemotherapy
|
June 13, 2012
Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval
Aylin Yilmaz, Victoria Watson, Laura Dickinson, et al.
AIDS (London, England)
|
October 3, 2003
Expression of P-glycoprotein, multidrug-resistance proteins 1 and 2 in CEM, CEM(VBL), CEM(E1000), MDCKII(MRP1) and MDCKII(MRP2) cell lines
Andrew Owen, Ruben C Hartkoorn, Saye Khoo, et al.
AIDS (London, England)
|
August 11, 2007
Stopping antiretroviral therapy
Stephen Taylor, Marta Boffito, Saye Khoo, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
October 18, 2005
Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry
Laura Dickinson, Lesley Robinson, John Tjia, et al.
Therapeutic Drug Monitoring
|
May 29, 2007
Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals
Laura Dickinson, David Back, Anton Pozniak, et al.
The Journal of Infectious Diseases
|
February 25, 2003
Differential expression of human immunodeficiency virus coreceptors, by CEM, CEMVBL, and CEM E1000 cells
Andrew Owen, Becky Chandler, Jenny Ford, et al.
Journal of the International AIDS Society
|
November 14, 2014
Should the dose of tenofovir be reduced to 200-250 mg/day, when combined with protease inhibitors?
Andrew Hill, Saye Khoo, David Back, et al.
Page
of 15